Leerink Partners Slashes PT on Merck & Co. (MRK) to $92 From $115

Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) on July 21, bringing the price target down to $92 from $115.

Merck’s (MRK) Dividend History: A Track Record of Consistency

A close-up of a person’s hand holding a bottle of pharmaceuticals.

The analyst told investors that Merck & Co., Inc.’s (NYSE:MRK) focus on the expansion of its cardiopulmonary and infectious disease franchises is anticipated to boost investor sentiment, especially because these domains show considerable development potential.

Graybosch reasoned that while challenges such as the regulatory pressures on Gardasil and Keytruda exist, Merck & Co., Inc.’s (NYSE:MRK) valuation remains attractive in comparison to its peers, which shows room for optimism and appreciation.

In addition, upcoming clinical trial results may also bolster Merck & Co., Inc.’s (NYSE:MRK) long-term revenue prospects according to the analyst, including those for enlicitide and Winrevair.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.

Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.